Waters Corporation stock climbed +12.74% in today’s session to close at $340.34 after the analytical instruments company released a first-quarter 2026 report ahead of the market that surpassed Wall Street expectations across major metrics.
On a per-share basis, Waters posted adjusted earnings of $2.70, outpacing the analyst consensus of $2.31 by $0.39. Revenue for the quarter reached $1.27 billion, topping the estimate of $1.20 billion. These results represented a clear upside on both the top and bottom lines, and they arrived alongside the first-quarter contribution from the businesses Waters acquired from Becton, Dickinson and Company.
The quarter was the first to include the Biosciences and Diagnostic Solutions businesses acquired on February 9, 2026. Management reported that the acquired businesses generated $520 million of revenue for the period, which was $40 million above the company’s internal guidance. On an organic basis, revenue grew 13% as reported and 11% in constant currency, beating the high end of Waters’ guidance range by 200 basis points.
Company leaders attribute the outperformance to intensified execution efforts. Waters described a 180-day revitalization plan that management says stepped up sales activity, tightened pricing discipline, and accelerated operational priorities. The Biosciences and Diagnostic Solutions businesses were singled out for rapid improvement, with management pointing to order growth and early realization of revenue synergies as signs of successful initial integration.
"Thanks to the hard work of our teams, we delivered an excellent first quarter as a combined company," said CEO Dr. Udit Batra, adding that the Biosciences and Advanced Diagnostics Divisions are "off to a strong start with a significant improvement in growth rates versus pre-close trends."
Following the results, Waters raised its full-year outlook. The company lifted its organic constant currency revenue growth guidance to 6.5–8.0% and increased its adjusted EPS guidance to $14.40–$14.60.
Analyst sentiment had been constructive ahead of the report. Goldman Sachs upgraded Waters to a "strong-buy" rating in a research note dated April 1, a move that the market had factored into expectations heading into the quarter.
Prior to the release, the stock had traded lower over recent periods, with shares down about 10% over the preceding two weeks and slightly negative over the past month. The earnings beat and guidance raise appear to have reversed that short-term weakness decisively. The company delivered an EPS surprise of $0.34, a 14.4% surprise versus consensus, while revenue topped estimates by 4.3%. For a company of Waters’ scale and maturity, the combination of a double-digit organic growth print, ahead-of-plan acquisition integration, and raised guidance is noteworthy and commonly linked to upward revisions to forward estimates.
The broader U.S. equity market provided a supportive backdrop on the day, with the S&P 500 rising +0.81%, the Dow Jones adding +0.58%, and the NASDAQ up +0.93%.
Results from peers in the life sciences tools and services segment had already signaled improving demand heading into Waters’ report. Avantor reported flat year-on-year revenue that beat estimates by 2.7%, while Thermo Fisher posted revenue growth of 6.2%, topping estimates by 1.5%. Those sector results set a constructive tone that Waters’ quarterly performance amplified.
The stock move recorded today ranks among the company’s largest single-session gains in recent memory, driven by the combined effects of stronger-than-expected organic growth, acquisition contributions exceeding plan, raised full-year guidance, and constructive market conditions.
Summary
Waters reported stronger-than-expected first-quarter 2026 results, including contributions from the newly acquired Biosciences and Diagnostic Solutions businesses. Organic revenue growth topped guidance, the acquisition outperformed internal expectations, and management raised full-year revenue and EPS guidance, prompting a sharp stock rally.
Key points
- Waters beat consensus on adjusted EPS ($2.70) and revenue ($1.27 billion) in Q1 2026, and shares rose +12.74% to $340.34.
- The Biosciences and Diagnostic Solutions businesses contributed $520 million, $40 million above guidance, while organic revenue rose 13% as reported and 11% in constant currency.
- Management raised full-year organic constant currency revenue growth guidance to 6.5–8.0% and adjusted EPS guidance to $14.40–$14.60; peers’ results signaled improving sector demand.
Risks and uncertainties
- The integration of the acquired businesses is in its early stages; the reported performance reflects initial improvements and early revenue synergy realization.
- Raised full-year guidance is contingent on sustained organic growth and the continued execution of operational priorities highlighted by management.
- Recent volatility - shares had been down roughly 10% over the prior two weeks and slightly for the month - indicates sensitivity to short-term sentiment and could influence future price action.